sucralfate (carafate) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Sucralfate (trade name CARAFATE) is a medication primarily taken to treat active duodenal ulcers. Sucralfate is also used for the treatment of gastroesophageal reflux disease (GERD) and stress ulcers. Sucralfate is a sucrose sulfate-aluminium complex that binds to the ulcer, creating a physical barrier that protects the gastrointestinal tract from stomach acid and prevents the degradation of mucus. Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.   NCATS

Chemistry

  • SMILES: O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
  • InChIKey: WXOMTJVVIMOXJL-BOBFKVMVSA-A
  • Mol. Mass: 2517.42
  • ALogP: Missing data
  • ChEMBL Molecules:
    sucralfate  
    sucralfate  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0739 - $8.9900
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

antepsin | carafate | hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-o-sulfo-β-dfructofuranosyl-α-d-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum | sucralate | sucralfat | sucralfate | sucralfato | sucralfatum | sucralfin | sucrate | sulcrate | ulcerlmin | ulcogant

Organizations (23)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (1)


 

Ulcer (approved 1981)

Experimental Indications - Clinical Trial Phases 1-4 (20)


 

Bacterial Infections (Phase 4)

Dyspepsia (Phase 4)

Eosinophilic Esophagitis (Early Phase 1)

Esophageal Neoplasms (Phase 3)

Esophagitis (Phase 2)

Gastritis (Phase 4)

Gingival Diseases (Phase 2)

Hand, Foot and Mouth Disease (Phase 2)

Head and Neck Neoplasms (Phase 3)

Hemorrhage (Phase 1)

Herpangina (Phase 2)

Laryngeal Neoplasms (Phase 3)

Mediastinal Neoplasms (Phase 3)

Mouth Neoplasms (Phase 3)

Mucositis (Phase 3)

Neoplasms (Phase 3)

Oropharyngeal Neoplasms (Phase 3)

Pneumonia, Ventilator-Associated (Phase 4)

Proctitis (Phase 4)

Ulcer (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue